Dear John,

ICYMI, Rachel Bonesteel joined Health Affairs This Week to discuss her recent Forefront article focused on how ACO REACH enabled ACOs to participate in an advanced, global-risk, population-based payment model.

Today's Featured Articles

Associations Between Dependent-Related Job Lock And Adult Mental And Physical Health

Tiffany L. Lemon et al.

Extending Enhanced Premium Tax Credits: Where Things Stand

Katie Keith

part of our Health Policy At A Crossroads series

Former Federal Employees Lead Coalition To Address Antimicrobial Resistance

Jomana F. Musmar et al.

Modernizing The Medicare Physician Fee Schedule: Non-Paid Activities Call For Hybrid Payment For Primary Care

Laura Skopec and Robert A. Berenson

Prior Authorization Reform Heats Up

Leila Sullivan et al.

More on Medicare Physician Fee Schedule

Modernizing The Medicare Physician Fee Schedule, Part 1: The Role Of A Technical Expert Panel

Robert A. Berenson (July 2025)

Strengths And Weaknesses Of Introducing An Inflation Factor Into The Medicare Physician Fee Schedule

Michael E. Chernew et al. (December 2024)

The Road To Value Can’t Be Paved With A Broken Medicare Physician Fee Schedule

Robert A. Berenson and Kevin J. Hayes (July 2024)

Ask the Health Affairs Editors

Join Health Affairs on December 3 for an exclusive Insider virtual event to hear our editors discuss 2025's most memorable submissions and take audience questions.

Become an Insider today to get access to this exclusive event.

Follow-On Cancer Drugs Target Earlier Stages Than Initial Drugs: Implications Of The IRA

In an ahead-of-print article published this month, Tomas J. Philipson and coauthors explore how mandates from the Inflation Reduction Act (IRA) resulted in shortening the exclusivity period used to recoup research and development investments as well as support follow-on innovation.

The study shows that oncology follow-on approvals frequently shift to earlier disease stages, a trend that may be accelerated by IRA-induced incentives.